Early detection of access dysfunction and timely intervention may enhance
vascular access survival and help to ensure delivery of prescribed
hemodialysis therapy.2 A standard feature on all 2008T hemodialysis systems,
OLC with access flow provides:
On-screen, step-by-step instruction for
monthly access flow measurement when
used in conjunction with the Twister®
reverse-flow bloodline
Trending of access flow which permits
intervention at patient-specific limits
before access failure
2Sands, J.Vascular Access: “The Past, Present, and Future.”
 Blood Purification 27: 22-27, 2009





Fresenius Logo

Caution: Federal (US) law restricts these devices to sale by or on the order of a physician.

Note: Read the Instructions for Use for safe and proper use of these devices. For a complete description of hazards, contraindications, side effects and precautions, see full package labeling at www.fmcna.com.

This site is intended for visitors from the United States.

© 2013-2017, Fresenius Medical Care, All Rights Reserved. Fresenius Medical Care, the triangle logo, Fresenius Renal Technologies, 2008, bibag, DIASAFE, Fresenius Polysulfone, Twister, Crit-Line, CLiC, and Clinical Data eXchange (CDX) are trademarks of Fresenius Medical Care Holdings, Inc., or its affiliated companies. Citrasate is a registered trademark of Advanced Renal Technologies in the United States and is used under license from Advanced Renal Technologies. All other trademarks are the property of their respective owners. P/N 102054-01 Rev C 10/2017